189 related articles for article (PubMed ID: 37734877)
1. Bispecific antibody CD73xEGFR more selectively inhibits the CD73/adenosine immune checkpoint on cancer cells and concurrently counteracts pro-oncogenic activities of CD73 and EGFR.
Ploeg EM; Samplonius DF; Xiong X; Ke X; Hendriks MAJM; Britsch I; van Wijngaarden AP; Zhang H; Helfrich W
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37734877
[TBL] [Abstract][Full Text] [Related]
2. A Novel Bispecific Antibody for EpCAM-Directed Inhibition of the CD73/Adenosine Immune Checkpoint in Ovarian Cancer.
Ploeg EM; Britsch I; van Wijngaarden AP; Ke X; Hendriks MAJM; Samplonius DF; Helfrich W
Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509310
[TBL] [Abstract][Full Text] [Related]
3. Bispecific antibody CD73xEpCAM selectively inhibits the adenosine-mediated immunosuppressive activity of carcinoma-derived extracellular vesicles.
Ploeg EM; Ke X; Britsch I; Hendriks MAJM; Van der Zant FA; Kruijff S; Samplonius DF; Zhang H; Helfrich W
Cancer Lett; 2021 Aug; 521():109-118. PubMed ID: 34464670
[TBL] [Abstract][Full Text] [Related]
4. Targeting two distinct epitopes on human CD73 with a bispecific antibody improves anticancer activity.
Gammelgaard OL; Terp MG; Renn C; Labrijn AF; Hamaker O; Nielsen AY; Vever H; Hansen SW; Gjerstorff MF; Müller CE; Parren PW; Ditzel HJ
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36096528
[TBL] [Abstract][Full Text] [Related]
5. Bispecific antibody approach for EGFR-directed blockade of the CD47-SIRPα "don't eat me" immune checkpoint promotes neutrophil-mediated trogoptosis and enhances antigen cross-presentation.
Hendriks MAJM; Ploeg EM; Koopmans I; Britsch I; Ke X; Samplonius DF; Helfrich W
Oncoimmunology; 2020 Sep; 9(1):1824323. PubMed ID: 33299654
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and pharmacodynamic effect of anti-CD73 and anti-PD-L1 monoclonal antibodies in combination with cytotoxic therapy: observations from mouse tumor models.
Kaistha BP; Kar G; Dannhorn A; Watkins A; Opoku-Ansah G; Ilieva K; Mullins S; Anderton J; Galvani E; Garcon F; Lapointe JM; Brown L; Hair J; Slidel T; Luheshi N; Ryan K; Hardaker E; Dovedi S; Kumar R; Wilkinson RW; Hammond SA; Eyles J
Cancer Biol Ther; 2024 Dec; 25(1):2296048. PubMed ID: 38206570
[TBL] [Abstract][Full Text] [Related]
7. GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma.
Park JA; Cheung NV
J Hematol Oncol; 2020 Dec; 13(1):172. PubMed ID: 33303017
[TBL] [Abstract][Full Text] [Related]
8. A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response.
Rubio-Pérez L; Lázaro-Gorines R; Harwood SL; Compte M; Navarro R; Tapia-Galisteo A; Bonet J; Blanco B; Lykkemark S; Ramírez-Fernández Á; Ferreras-Gutiérrez M; Domínguez-Alonso C; Díez-Alonso L; Segura-Tudela A; Hangiu O; Erce-Llamazares A; Blanco FJ; Santos C; Rodríguez-Peralto JL; Sanz L; Álvarez-Vallina L
Oncoimmunology; 2023; 12(1):2205336. PubMed ID: 37114242
[TBL] [Abstract][Full Text] [Related]
9. Modulating tumor infiltrating myeloid cells to enhance bispecific antibody-driven T cell infiltration and anti-tumor response.
Park JA; Wang L; Cheung NV
J Hematol Oncol; 2021 Sep; 14(1):142. PubMed ID: 34496935
[TBL] [Abstract][Full Text] [Related]
10. Development of a c-MET x CD137 bispecific antibody for targeted immune agonism in cancer immunotherapy.
Zhang H; Wang Q; Yalavarthi S; Pekar L; Shamnoski S; Hu L; Helming L; Zielonka S; Xu C
Cancer Treat Res Commun; 2024; 39():100805. PubMed ID: 38492435
[TBL] [Abstract][Full Text] [Related]
11. Bispecific antibody simultaneously targeting PD1 and HER2 inhibits tumor growth via direct tumor cell killing in combination with PD1/PDL1 blockade and HER2 inhibition.
Gu CL; Zhu HX; Deng L; Meng XQ; Li K; Xu W; Zhao L; Liu YQ; Zhu ZP; Huang HM
Acta Pharmacol Sin; 2022 Mar; 43(3):672-680. PubMed ID: 33990766
[TBL] [Abstract][Full Text] [Related]
12. A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpoint.
Koopmans I; Hendriks D; Samplonius DF; van Ginkel RJ; Heskamp S; Wierstra PJ; Bremer E; Helfrich W
Oncoimmunology; 2018; 7(8):e1466016. PubMed ID: 30221065
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target.
Le X; Negrao MV; Reuben A; Federico L; Diao L; McGrail D; Nilsson M; Robichaux J; Munoz IG; Patel S; Elamin Y; Fan YH; Lee WC; Parra E; Solis Soto LM; Chen R; Li J; Karpinets T; Khairullah R; Kadara H; Behrens C; Sepesi B; Wang R; Zhu M; Wang L; Vaporciyan A; Roth J; Swisher S; Haymaker C; Zhang J; Wang J; Wong KK; Byers LA; Bernatchez C; Zhang J; Wistuba II; Gibbons DL; Akbay EA; Heymach JV
J Thorac Oncol; 2021 Apr; 16(4):583-600. PubMed ID: 33388477
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody.
Lu D; Zhang H; Ludwig D; Persaud A; Jimenez X; Burtrum D; Balderes P; Liu M; Bohlen P; Witte L; Zhu Z
J Biol Chem; 2004 Jan; 279(4):2856-65. PubMed ID: 14576153
[TBL] [Abstract][Full Text] [Related]
15. Targeting tumor vasculature to improve antitumor activity of T cells armed ex vivo with T cell engaging bispecific antibody.
Park JA; Espinosa-Cotton M; Guo HF; Monette S; Cheung NV
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36990507
[TBL] [Abstract][Full Text] [Related]
16. PD-1/LAG-3 bispecific antibody potentiates T cell activation and increases antitumor efficacy.
Shi N; Zhou Y; Liu Y; Zhang R; Jiang X; Ren C; Gao X; Luo L
Front Immunol; 2022; 13():1047610. PubMed ID: 36518768
[TBL] [Abstract][Full Text] [Related]
17. In vivo studies using bispecific antibodies (anti-CD3 x anti-idiotype) and CD28-induced costimulation in the BCL1 lymphoma.
Demanet C; Brissinck J; De Jonge J; Thielemans K
J Hematother; 1995 Oct; 4(5):363-8. PubMed ID: 8581370
[TBL] [Abstract][Full Text] [Related]
18. Tumor intrinsic and extrinsic functions of CD73 and the adenosine pathway in lung cancer.
Kowash RR; Akbay EA
Front Immunol; 2023; 14():1130358. PubMed ID: 37033953
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of bispecific monoclonal antibody (bsAb)-targeted cytolysis by human anti-mouse antibodies in ovarian carcinoma patients treated with bsAb-targeted activated T-lymphocytes.
Lamers CH; Gratama JW; Warnaar SO; Stoter G; Bolhuis RL
Int J Cancer; 1995 Feb; 60(4):450-7. PubMed ID: 7829257
[TBL] [Abstract][Full Text] [Related]
20. Single variable domain antibody as a versatile building block for the construction of IgG-like bispecific antibodies.
Shen J; Vil MD; Jimenez X; Zhang H; Iacolina M; Mangalampalli V; Balderes P; Ludwig DL; Zhu Z
J Immunol Methods; 2007 Jan; 318(1-2):65-74. PubMed ID: 17126853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
